<DOC>
	<DOC>NCT01418521</DOC>
	<brief_summary>The purpose of this randomized controlled trial in patients undergoing cardiac surgery is to show that a 3rd generation HES (Hydroxyethyl Starch) solution - Tetraspan® is as good as in terms of safety and effectiveness as the commonly used albumin based solution for volume replacement after the surgery.</brief_summary>
	<brief_title>Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>Written informed consent must be obtained from the subject or his/her legal guardian before any assessment is performed. Male or Female subject, 18 years or older. Any elective cardiac surgery Subjects with impaired liver function defined as an elevated level of ALT and AST over 100 U/L. Hyperhydration states (e.g. pulmonary edema, congestive heart failure). Renal failure with creatinine blood levels &gt; 2.5 mg/dL or eGFR &lt; 30 ml/min (calculated using the DMRD formula). Oliguria (UO&lt;0.5ml\kg\hr) or anuria (not related to hypovolemia) more than 12 hours. Current Intracranial hemorrhage. Current, hard to balance hyperkalemia. Severe hypernatremia or severe hyperchloremia. Known hypersensitivity to hydroxyethyl starch or to any of the excipients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Cardiac surgery</keyword>
	<keyword>Balanced 3rd generation Hydroxyethyl starch</keyword>
	<keyword>Tetraspan</keyword>
	<keyword>Ringer-albumin</keyword>
</DOC>